## **CLAIMS**

- A method of glucose level control, comprising:
   providing at least one electrode adapted to apply an electric field to a pancreas; and applying an electric field to the pancreas using said at least one electrode such that blood glucose levels are significantly reduced and blood insulin levels are not significantly increased.
- 2. A method according to claim 1, comprising subsequently applying a second electric field to said pancreas, which second field increases insulin levels.
  - 3. A method according to claim 1, wherein said electric field is operative to reduce glucagon secretion.
  - 4. A method according to claim 1, wherein said electric field is operative to reduce glucose secretion by a liver physiologically coupled to said pancreas.

15

- 5. A method according to claim 1, wherein said electric field is operative to increase glucose uptake by cells in a body containing said pancreas.
  - 6. A method according to claim 1, wherein said electric field is operative to affect nervous tissue in said pancreas.
- 7. A method according to claim 1, wherein said electric field is non-excitatory in that it does not substantially induce new bursts of islet activity in said pancreas.
  - 8. A method according to claim 1, wherein said electric field is applied as a bi-phasic and charge balanced time varying field.
  - 9. A method according to claim 8, wherein said electric field is applied for a short duration every period of time.

10. A method according to claim 9, wherein said period of time gives an application frequency of between 1Hz and 15 Hz.

- 11. A method according to claim 9, wherein said period of time gives an application frequency of about 5 Hz.
  - 12. A method according to claim 9, wherein said duration is less than 30 ms.
  - 13. A method according to claim 9, wherein said duration is about 10 ms.

10

- 14. A method according to claim 1, wherein said electric field is repeated for a period of less than 30 minutes.
- 15. A method according to claim 1, wherein said electric field is repeated for a period of between 30 and 180 minutes.
  - 16. A method according to claim 1, wherein said electric field is applied for substantially all of a duration of a glucose absorption event.
- 20 17. A method according to claim 1, wherein said electric field is applied prior to an expected glucose ingestion event.
  - 18. A method according to claim 1, comprising triggering said electric field by a glucose ingestion event.

- 19. A method according to claim 1, wherein said electric field is applied irrespectively of an ingestion event.
- 20. A method according to claim 1, wherein said electric field is applied at least part of the time irrespective of a blood glucose level.
  - 21. A method according to claim 1, wherein said electric field is applied continuously for at least 24 hours.

22. A method according to claim 1, wherein said electric field is applied for a period of at least 15 minutes without sensing of its effect.

- 23. A method according to claim 1, wherein said electric field is of a magnitude and temporal extent so that it does not significantly change blood insulin and glucose levels in the absence of an ingestion event.
  - 24. A method according to claim 1, wherein said electric field reduces blood glucose levels by at least 20% of an elevation of the glucose level above a fasting baseline glucose level.

10

- 25. A method according to claim 1, wherein said electric field does not increase blood insulin levels, as measured by an average over five minutes, by more than 20%.
- 26. A method according to claim 1, comprising, delaying a gastric emptying by applying a treatment to the stomach.
  - 27. A method according to claim 1, wherein said electric field is operative to delay a glucose peak at least by a duration of its application.
- 28. A method according to claim 1, wherein said electric field is operative to delay a glucose peak at least by 10 minutes.
  - 29. A method according to claim 1, wherein said electric field is operative to delay an insulin peak at least by 10 minutes.

25

30. A method of glucose level control, comprising: providing at least one electrode adapted to apply an electric field to a pancreas; and applying an electric field to the pancreas operative to reduce blood glucose levels if elevated and not significantly reduce such levels if not substantially elevated.

30

31. A method according to claim 30, wherein said electric field reduces elevated glucose levels by at least 20%.

32. A method according to claim 30, wherein said electric field does not reduce unelevated glucose levels by more than 10%

33. A method according to claim 30, wherein said electric field does not impair exocrine functions of said pancreas.

5

- 34. Apparatus for blood glucose control, comprising:

  at least one electrode adapted to apply an electric field to a pancreas; and
  circuitry adapted to electrify said at least one electrode and configured to electrify said
  electrode in a manner which compensates for a loss of acute response by said pancreas.
  - 35. Apparatus according to claim 34, wherein said circuitry compensates by causing the secretion of an insulin bolus.
- 15 36. Apparatus according to claim 34, wherein said circuitry compensates by reducing glucose levels in a non-insulin manner.
  - 37. Apparatus according to claim 36, wherein said circuitry compensates by reducing glucagon secretion.
  - 38. Apparatus according to claim 34, wherein said circuitry reduces or prevents a substantial increase in insulin secretion during said compensation.
- 39. Apparatus according to claim 34, wherein for at least 20% of ingestion events said circuitry applies only an acute control of insulin levels.
  - 40. Apparatus according to claim 39, wherein said apparatus is programmed with a knowledge of a slow acting chemical-based insulin therapy provided to said pancreas.
- 30 41. Apparatus according to claim 34, comprising an automatic ingestion sensor for automatically detecting an ingestion event.
  - 42. Apparatus according to claim 34, comprising an automatic glucose sensor for automatically detecting a situation requiring an acute response.

43. Apparatus according to claim 34, comprising an automatic glucose sensor for automatically detecting a situation requiring an acute insulin response.

- 5 44. Apparatus according to claim 34, wherein said response is an acute insulin response.
- 45. Apparatus for blood glucose control, comprising:

  at least one electrode adapted to apply an electric field to a pancreas; and

  circuitry adapted to electrify said at least one electrode and configured to electrify said

  electrode in a manner which significantly reduces elevated blood glucose levels, said circuitry

  configured to apply said field also when glucose levels are not elevated.
  - 46. Apparatus according to claim 45, wherein said circuitry is a closed loop system including sensing of the effect of the electrification and wherein said circuitry is configured to over stimulate in cases of doubt.

- 47. Apparatus according to claim 45, wherein said circuitry is a semi-open loop system where a relatively long stimulation series is applied without feedback.
- 48. Apparatus according to claim 45, wherein said circuitry is an open loop system where a stimulation series is applied responsive to a trigger and without feedback.
- 49. Apparatus for blood glucose control, comprising:

  at least electrode adapted to apply an electric field to pancreatic tissue; and

  circuitry adapted to electrify said at least one electrode and configured to electrify said electrode in a manner which reduces glucose levels and does not substantially elevate insulin levels above a baseline value, when glucose levels are elevated.
- 50. Apparatus according to claim 49, wherein said circuitry is a closed loop system including sensing of the effect of the electrification and wherein said circuitry is configured to over stimulate in cases of doubt.
  - 51. Apparatus according to claim 49, wherein said circuitry is a semi-open loop system where a relatively long stimulation series is applied without feedback.

52. Apparatus according to claim 49, wherein said circuitry is an open loop system where a stimulation series is applied responsive to a trigger and without feedback.

- 5 53. Apparatus according to claim 49, wherein said circuitry applies a constant voltage field.
  - 54. Apparatus according to claim 49, wherein said circuitry applies a constant current field.
- 55. Apparatus according to claim 49, wherein said pancreatic tissue comprises an in-vivo pancreas.

10

56. Apparatus according to claim 49, wherein said pancreatic tissue comprises a pancreatic tissue implant.